A Phase 1, Fixed−Sequence, Open−Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD−9855 in Healthy Subjects

Trial Profile

A Phase 1, Fixed−Sequence, Open−Label Drug-Drug Interaction Study to Assess the Effect of Fluvoxamine (CYP1A2 Inhibitor), Cigarette Smoking (CYP1A2 Inducer) and Itraconazole (CYP3A4 Inhibitor) on the Pharmacokinetics of TD−9855 in Healthy Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 28 Jun 2018

At a glance

  • Drugs TD 9855 (Primary) ; Caffeine; Fluvoxamine; Itraconazole
  • Indications Orthostatic hypotension
  • Focus Pharmacokinetics
  • Sponsors Theravance Biopharma
  • Most Recent Events

    • 18 Jun 2018 Status changed from not yet recruiting to completed.
    • 16 Feb 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top